| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 69.73 | 13.5% | 23.1% |
| Total Income | 69.73 | 13.5% | 23.1% |
| Expenditure | 52.83 | 7.8% | 30.9% |
| PBT | — | ||
| Net Profit | -1.52 | 92.2% | 362.1% |
| OPM | -3.09% | 1.52pp | 6.04pp |
| NPM | -2.17% | 29.69pp | 3.20pp |
| EPS | -0.03 | 92.1% | 400.0% |
Axogen Reports Q2 2026 Financial Results and Raises Full Year Revenue Guidance
29 Jul 2026 · 29 Jul, 4:46 pm
Summary
Axogen, Inc. announced its second quarter 2026 financial results, reporting a 23.1% year-over-year increase in revenue to $69.7 million. While gross margin slightly decreased to 72.7% from 74.2%, this was attributed to strong growth in the Breast segment. The company posted a net loss of $1.5 million for the quarter, but adjusted net income rose to $7.3 million. Axogen raised its full-year 2026 revenue guidance to at least 24% growth, expecting at least $279 million in revenue, and anticipates positive free cash flow for the full year.
Key Highlights
- 1
Axogen reported second quarter 2026 revenue of $69.7 million, an increase of 23.1% compared to $56.7 million in the second quarter of 2025.
- 2
Gross margin for the second quarter was 72.7%, compared to 74.2% in the prior year period, driven by accelerating year-over-year Breast growth greater than 50%.
- 3
The company reported a net loss of $1.5 million, or $0.03 per share, for the second quarter of 2026, compared to a net income of $0.6 million, or $0.01 per share, in the second quarter of 2025.
- 4
Adjusted net income for the second quarter was $7.3 million, or $0.12 per share, an increase from $5.7 million, or $0.12 per share, in the second quarter of 2025.
- 5
Adjusted EBITDA for the second quarter was $8.4 million, compared to $9.3 million for the second quarter of 2025.
- 6
Axogen raised its full-year 2026 revenue guidance to at least 24% growth, projecting at least $279 million in revenue.
- 7
The company reported year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast segments.
Management Comments
Michael Dale
We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities. Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026.
Informational and educational content only. Not investment advice.